The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.
 
Dominick Bosse
No Relationships to Disclose
 
Wanling Xie
No Relationships to Disclose
 
Aly-Khan A. Lalani
No Relationships to Disclose
 
Guillermo de Velasco
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - Astellas Medivation; Bayer; Janssen; Novartis; Pfizer
Other Relationship - Janssen
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Pheroze Tamboli
No Relationships to Disclose
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Medivation/Astellas; Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Sotio (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer; Cerulean Pharma; Exelixis
 
Kimryn Rathmell
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (I); Merck (I); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Amgen; Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Janssen; Merck; Novartis; Pfizer; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim
 
Sabina Signoretti
No Relationships to Disclose
 
A. Ari Hakimi
No Relationships to Disclose
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy